Icotinib Hydrochloride in Treating Patients With Advanced Cancers

NCT02033148 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped changes in study design by sponsor not acceptable for participating

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: icotinib hydrochloride
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

Roswell Park Cancer Institute